A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis With an Inadequate Response to Conventional Therapy
A Phase 2/3, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Oral Ozanimod (RPC1063) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis With an Inadequate Response to Conventional Therapy
The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod will be administered orally to pediatric participants with moderate to severe active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.
Inclusion Criteria
Exclusion Criteria
Clinical.Trials@bms.com855-907-3286
Worcester, Massachusetts 01655, United States
Chapel Hill, North Carolina 27599, United States
Haifa, Northern District 3109601, Israel
04-7774381
Kurume-shi, Fukuoka 8300011, Japan
+81-942-35-3311
Bunkyo-Ku, Tokyo 113-8519, Japan
+81-3-5803-5877
Setagaya-ku, Tokyo 1578535, Japan
+81-3-3416-0181
Shinjuku-ku, Tokyo 160-0023, Japan
81333426111
Wroclaw, Lower Silesian Voivodeship 50-369, Poland
505-274-0704
310-423-7100
650-721-2250
310-597-1251
207-662-5522
617-699-1021
774-441-8082
111111
513-518-8949
212-305-5903
216444231
832-822-3612
111111
503-847-4748
0298453999
+61395943577
003216343343
32 4321 54 67
0685946782
33668354806
+49-341-9726111
03-9253673
02-6666482
81562430500
81-761-22-7111
+81455763000
81-726-83-1221
+81-3-3813-3111
+48 71 7703045
+48603508908
+48500111648
+48664929399
787-723-5945
07788861236
02032991674
02035942473